INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

NUVLNuvalent, Inc.

CIK 0001861560

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 31
Max Insider Score29
Connections8with evidence

NUVL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
OJ
Oliger Christy J.Director
NUVLNuvalent, Inc.
Grant or award
A—
3,444 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Oliger Christy J.Director · Jun 18, 2026
  • ← Insider ofevidence
    Porter James RichardDirector, President and CEO · Apr 8, 2026
  • ← Insider ofevidence
    Lane BenjaminSee Remarks · Apr 2, 2026
25
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL
$2.46M
20.0K sh
Jun 9, 2026
Jun 11, 2026
traded Jun 9, 2026
+2d
SEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$176K
9,315 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
685 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

4
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
9,315 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$11K
10.0K sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$4,720
685 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

17
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.10M
12.5K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

17
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.28M
14.5K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

14
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$272K
3,036 sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

0
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
30.0K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

2
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$568K
30.0K sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

2
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$153K
5,500 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$138K
1,300 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$153K
1,422 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$164K
1,500 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

11
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
100 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

0
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

0
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$97K
900 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$164K
1,530 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

0
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$38K
5,500 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$149K
1,401 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$182K
1,669 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

14
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$127K
1,178 sh
May 28, 2026Jun 1, 2026
traded May 28, 2026
+4dSEC FORM 4

Evidence

7
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$754K
7,429 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

14
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.77M
17.4K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

4
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$217K
2,111 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

3
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
30.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

5
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$568K
30.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

4
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$167K
1,699 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

4
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
1,408 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
PE
Pelish Henry E.Chief Scientific Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$86K
3,093 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

16
PE
Pelish Henry E.Chief Scientific Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$229K
2,193 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

4
PE
Pelish Henry E.Chief Scientific Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
3,093 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

16
PE
Pelish Henry E.Chief Scientific Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$95K
900 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

20
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
100 sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

5
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$260K
13.7K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

5
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$454K
16.3K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

29
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.17M
11.4K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

29
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.29M
12.4K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

26
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$641K
6,121 sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

3
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
13.7K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

3
PR
Porter James RichardDirector, President and CEO
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
16.3K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

17
LB
Lane BenjaminSee Remarks
NUVLNuvalent, Inc.
Grant or award
A—
9,500 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

9
LB
Lane BenjaminSee Remarks
NUVLNuvalent, Inc.
Grant or award
A—
19.0K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

23
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$247K
2,532 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

26
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$291K
2,968 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

3
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

6
ND
Noci DarleneChief Development Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$153K
5,500 sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC FORM 4

Evidence

26
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$279K
2,803 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

3
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$38K
5,500 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

23
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$92K
940 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

23
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$173K
1,757 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

3
MA
Miller Deborah AnnChief Legal Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$12K
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

23
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$247K
2,599 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

29
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Open-market sale · 10b5-1 plan
SELL$1.37M
13.7K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Noci DarleneChief Development Officer · Apr 1, 2026
  • ← Insider ofevidence
    Miller Deborah AnnChief Legal Officer · Mar 30, 2026
  • ← Insider ofevidence
    Balcom AlexandraChief Financial Officer · Mar 26, 2026
  • ← Insider ofevidence
    Pelish Henry E.Chief Scientific Officer · Mar 16, 2026